10 July 2020 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has provided additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir.

The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual) and include a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19.

In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality compared with standard of care an important finding that requires confirmation in prospective clinical trials.

Separate subgroup analyses from the Phase 3 SIMPLE-Severe trial, including an evaluation of the safety and efficacy of remdesivir across different racial and ethnic patient subgroups treated in the United States, found that traditionally marginalised racial or ethnic groups treated with remdesivir in this study experienced similar clinical outcomes as the overall patient population in the study.

Gilead is also presenting new analyses of the company's compassionate use program, which demonstrated that 83% of pediatric patients and 92% of pregnant and postpartum women with a broad spectrum of disease severity recovered by Day 28.

No new safety signals were identified with remdesivir across these populations.

To further the understanding of these results in individual patient cases, Gilead recently announced the initiation of a global, open-label Phase 2/3 trial to evaluate the safety, tolerability and pharmacokinetics of remdesivir in pediatric patients from birth to less than 18 years of age.

Gilead is also collaborating on a study for pregnant women.

This comparative pre-planned analysis included 312 patients treated in the Phase 3 SIMPLE-Severe study and a separate real-world retrospective cohort of 818 patients with similar baseline characteristics and disease severity who received standard of care treatment in the same time period as the SIMPLE-Severe study.

Patients were primarily located in North America (92%, remdesivir cohort vs. 91%, standard-of-care cohort), Europe (5% vs. 7%) and Asia (3% vs. 2%).

The analysis demonstrated that remdesivir treatment was associated with significantly improved clinical recovery and a 62% reduction in the risk of mortality compared to standard of care.

Findings from the comparative analysis showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59% of patients receiving standard of care; recovery was defined as improvement in clinical status based on a seven-point ordinal scale.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14 compared with 12.5% among patients not taking remdesivir (adjusted odds ratio 0.38, 95% confidence interval 0.22-0.68, p=0.001).

The results of this comparative analysis add to the previously presented National Institute of Allergy and Infectious Disease (NIAID) randomized, double-blind, placebo-controlled study in hospitalized patients with COVID-19, which showed that remdesivir shortened time to recovery by an average of four days as compared to placebo (11 vs. 15 days; p